Photo: Mikhail Svetlov/Getty Images

Russian President Vladimir Putin said on Wednesday that if the U.S. exits a Cold War-era missile treaty and begins developing new intermediate-range missiles, his country will follow suit, per the AP.

The backdrop: President Trump has threatened to withdraw from the landmark 1987 Intermediate-Range Nuclear Forces (INF) treaty — which bans land-based nuclear missiles in Europe — because Russia has developed and fielded a banned missile system. All 29 NATO members backed the U.S. accusation yesterday, saying: "It is now up to Russia to preserve the INF Treaty." Secretary of State Mike Pompeo said the U.S. would begin withdrawal in 60 days if Russia remains in violation.

Go deeper

Updated 55 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Politics: Chris Christie: Wear a mask "or you may regret it — as I did" — Senate Democrats block vote on McConnell's targeted relief bill.
  2. Business: New state unemployment filings fall.
  3. Economy: Why the stimulus delay isn't a crisis (yet).
  4. Health: FDA approves Gilead's remdesivir as a coronavirus treatment How the pandemic might endMany U.S. deaths were avoidable.
  5. Education: Boston and Chicago send students back home for online learning.
  6. World: Spain and France exceed 1 million cases.

FBI: Russian hacking group stole data after targeting local governments

FBI Headquarters. Photo: Mark Wilson/Getty Images

Energetic Bear, a Russian state-sponsored hacking group, has stolen data from two servers after targeting state and federal government networks in the U.S. since at least September, the FBI and Cybersecurity and Infrastructure Security Agency said on Thursday.

Driving the news: Director of National Intelligence John Ratcliffe announced Wednesday that Iran and Russia had obtained voter registration information that could be used to undermine confidence in the U.S. election system.

FDA approves Gilead's remdesivir as a coronavirus treatment

A production line of Remdesivir. Photo: Fadel Dawood/picture alliance via Getty Images

Gilead Sciences on Thursday received approval from the Food and Drug Administration for remdesivir, an antiviral treatment that has shown modest results against treating COVID-19.

Why it matters: It's the first and only fully FDA-approved drug in the U.S. for treating the coronavirus.